Sarepta Therapeutics (NASDAQ:SRPT) stock price target bumped up to $102.00, reported earlier today by Robert W. Baird
- Updated: September 19, 2016
Showing a price of $28.15, Sarepta Therapeutics (NASDAQ:SRPT) traded 91.30% higher on the day. The last stock price is up 163.13% from the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same time period. SRPT has recorded a 50-day average of $26.16 and 200-day average of $20.47. 29,541,278 shares of Sarepta Therapeutics exchanged hands, up from ann avg. volume of 2,328,380
Robert W. Baird bumped the estimated target of Sarepta Therapeutics (NASDAQ:SRPT) to $102, stating a possible upside of 2.62%,
On Friday July 22 2016, Needham released a statement for Sarepta Therapeutics(NASDAQ:SRPT) raised the target price from $20.00 to $26.00 that suggested an upside of 0.15%.
In addition to Robert W. Baird reporting it’s target price, a total of 13 brokerages have reported on SRPT. The consensus target is $20.77 with three analysts rating the stock a strong buy, one analyst rating the company a buy, five analysts rating the stock a hold, four brokerages rating the company to underperform, and lastly one firm rating the company as sell.
Sarepta Therapeutics has a 52 week low of $8.00 and a one-year high of $56.18 and has a market cap of $0.0.
Brief Synopsis On Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.